Recent Articles By The Author
These names both offer reasons to think their fortunes could turn as 2020 approaches.
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
Stemline Therapeutics and Entercom Communications seem to have stabilized after notable declines late in the summer.
As expected, the Federal Reserve cut interest rates by a quarter point. Investors are now reading the entrails of the comments that accompanied the announcement. The central bank removes the phrase that it will "act as appropriate" to sustain econom...